Takeda Pharmaceutical (TSE: 4502/NYSE: TAK) announced completion of its 7-year Phase 3 clinical trial for dengue vaccine QDENGA, showing the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE